Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Ciprofloxacin Pharmacokinetics/Pharmacodynamics against Susceptible and Low-Level Resistant Escherichia coli Isolates in an Experimental Ascending Urinary Tract Infection Model in Mice

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Olorofim Susceptibility Testing of 1,423 Danish Mold Isolates Obtained in 2018-2019 Confirms Uniform and Broad-Spectrum Activity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Increased short- and long-term mortality following infections in dementia: a nationwide registry-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Meropenem to Children With Febrile Neutropenia Induces Monoresistant Pseudomonas aeruginosa

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Therapeutic drug monitoring of β-lactam antibiotics

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Oral amoxicillin and amoxicillin–clavulanic acid: properties, indications, and usage

    Research output: Contribution to journalReviewpeer-review

View graph of relations

The mouse ascending urinary tract infection model was used to study the pharmacokinetic/pharmacodynamic (PKPD) relationships of the effect of ciprofloxacin in subcutaneous treatment for 3 days with varying doses and dosing intervals against a susceptible Escherichia coli strain (MIC, 0.032 mg/liter). Further, a humanized dose of ciprofloxacin was administered for 3 days against three E. coli strains with low-level resistance, i.e., MICs of 0.06, 0.25, and 1 mg/liter, respectively. Against the susceptible isolate, ciprofloxacin was highly effective in clearing the urine with daily doses from 10 mg/kg, but the dosing regimen had to be divided into at least two doses for optimal effect. Ciprofloxacin could not clear the urine or kidneys for the low-level-resistant strains. PKPD correlations with all strains combined showed that for the AUC24/MIC there was a slightly higher correlation with effect in urine and kidneys (R2, 0.71 and 0.69, respectively) than the %T>MIC (R2, 0.41 and 0.61, respectively). Equal correlations for the two PKPD indices were found for reduction of colony counts (CFU) in the bladder tissue, but not even the highest dose of 28 mg/kg × 6 could clear the bladder tissue. In conclusion, ciprofloxacin is highly effective in clearing the urine and kidney tissue for fully susceptible E. coli, while even low-level resistance in E. coli obscures this effect. While the effect of ciprofloxacin is mostly AUC/MIC driven against E. coli infection in the urinary tract, the effect in urine depends on the presence of ciprofloxacin in the urine during most of a 24-h period.

Original languageEnglish
Article numbere01804-20
JournalAntimicrobial Agents and Chemotherapy
Volume65
Issue number1
ISSN0066-4804
DOIs
Publication statusPublished - 2021

ID: 62326874